G
688393
vs
S
Shanghai Composite
Over the past 12 months, Guangzhou LBP Medicine Science & Technology Co Ltd has underperformed Shanghai Composite, delivering a return of -10% compared to the Shanghai Composite's +23% growth.
Stocks Performance
688393 vs Shanghai Composite
Performance Gap
688393 vs Shanghai Composite
Performance By Year
688393 vs Shanghai Composite
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Guangzhou LBP Medicine Science & Technology Co Ltd
Glance View
Guangzhou LBP Medicine Science & Technology Co., Ltd. engages in the research and development, production, and sale of in vitro diagnostic reagents and instruments. The company is headquartered in Guangzhou, Guangdong and currently employs 697 full-time employees. The company went IPO on 2020-08-20. The Company’s main products are pathological diagnostic reagents and instruments, covering three major technology platforms for cytological diagnosis, molecular diagnosis and immunodiagnosis, including LBP series, IHC series, PCR series and FISH series, such as integrated slide and dyeing machine, liquid-based cell and microorganism processing, preservation reagents, automatic nucleic acid molecular hybridization instrument, automatic slide processing system and immunochromogenic reagents, etc. Its products are mainly used in pathological diagnosis of tumors. The firm operates its businesses within the domestic market and to overseas markets.
